Molecular profiling to improve risk stratification in appendiceal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study analyzes archived appendiceal cancer tissues to map DNA methylation patterns and m6A epitranscriptomic features. It aims to define molecular subtypes and construct continuous risk scores that complement histologic grading. Data from matched clinicopathologic and follow-up information are used to explore associations with survival, progression, and other clinical factors. The approach leverages formalin-fixed paraffin-embedded tissues and, when available, benign appendix samples. Findings may inform future risk stratification alongside conventional pathology.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer.
* Availability of archived tumor tissue suitable for molecular profiling.
* Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both.
* Availability of relevant clinicopathologic data.
* Availability of survival or follow-up information when applicable.
* Age 18 years or older at diagnosis or tissue collection.

Exclusion Criteria:

* Insufficient tissue quantity or quality for molecular profiling.
* Inadequate DNA or RNA quality for sequencing or molecular assay preparation.
* Missing essential clinicopathologic information required for analysis.
* Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site.
* Patients who do not meet institutional review board or consent requirements, if applicable.

Where it's running

• City of Hope Medical Center
  Durate, California, United States Recruiting

Study contacts

• Study coordinator: Ajay Goel
• Email: ajgoel@coh.org
• Phone: 6262184673

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating the genetics of appendix cancer

  This study is trying to find out how genetics might play a role in appendix cancer by following adults with the disease for up to six years.

  Recruiting Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT05734430

• Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread

  This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07795749

• TLR9-based immunotherapy for peritoneal cancer with ascites

  This trial tests ACM-CpG injections into the abdomen to see if it’s safe and can help people with peritoneal metastases or malignant ascites from colorectal or appendiceal cancer.

  Recruiting Phase 1 Brown University · Providence, Rhode Island · NCT07658196

• Mass-based drug screening to guide personalized HIPEC for high-grade appendiceal and colorectal cancer with peritoneal spread.

  This tests whether a lab-based mass response test on tumor biopsies can pick the best chemotherapy to use during repeated HIPEC for people with unresectable peritoneal metastases from high-grade appendiceal or colorectal cancer.

  Recruiting Yale University · New Haven, Connecticut · NCT07291180

• Intraoperative imaging of gastrointestinal cancers using pafolacianine (CYTALUX™)

  This trial will test whether an injection of CYTALUX™ (pafolacianine) with near-infrared imaging helps surgeons find gastric, esophageal, or appendiceal adenocarcinomas during surgery in adults.

  Recruiting Phase 4 Cedars-Sinai Medical Center · Los Angeles, California · NCT07124351

• Combining local therapy with ongoing systemic treatment for certain cancers

  This study is testing whether adding local treatments to ongoing systemic therapy can help people with certain cancers keep their disease under control for longer.

  Recruiting University of California, Davis · Sacramento, California · NCT06101277

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.